Literature DB >> 14557636

HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences.

R S Midgley1, A I Bell, Q Y Yao, D Croom-Carter, A D Hislop, B M Whitney, A T C Chan, P J Johnson, A B Rickinson.   

Abstract

An individual's CD8(+)-cytotoxic-T-lymphocyte (CTL) response to Epstein-Barr virus (EBV) latent cycle antigens focuses on a small number of immunodominant epitopes often presented by just one of the available HLA class I alleles; for example, HLA-A11-positive Caucasians frequently respond to two immunodominant HLA A11 epitopes, IVTDFSVIK (IVT) and AVFDRKSDAK (AVF), within the nuclear antigen EBNA3B. Here, we reexamine the spectrum of EBV strains present in the highly HLA-A11-positive Chinese population for sequence changes in these epitopes relative to the Caucasian type 1 prototype strain B95.8. The IVT epitope was altered in 61 of 64 Chinese type 1 viruses, with four different sequence variants being observed, and the AVF epitope was altered in 46 cases with six different sequence variants; by contrast, all 10 Chinese type 2 viruses retained the prototype 2 epitope sequences. All but one of the type 1 epitope variants were poorly recognized by IVT- or AVF-specific CTLs in pulse-chase assays of peptide-mediated target cell lysis. More importantly, we screened HLA-A11-positive Chinese donors carrying viruses with known epitope mutations for evidence of epitope-specific CTL memory by enzyme-linked immunospot assays: none of the type 1 variants tested, nor the type 2 prototype, appeared to be immunogenic in vivo. The data remain consistent with the possibility that, during virus-host coevolution, pressure from the host CTL-mediated immune response has given A11 epitope-loss viruses a selective advantage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557636      PMCID: PMC229266          DOI: 10.1128/jvi.77.21.11507-11516.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Novel intertypic recombinants of epstein-barr virus in the chinese population.

Authors:  R S Midgley; N W Blake; Q Y Yao; D Croom-Carter; S T Cheung; S F Leung; A T Chan; P J Johnson; D Huang; A B Rickinson; S P Lee
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Toward a comprehensive phylogeny for mammalian and avian herpesviruses.

Authors:  D J McGeoch; A Dolan; A C Ralph
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules.

Authors:  Nilabh Shastri; Susan Schwab; Thomas Serwold
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 4.  Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses.

Authors:  J W Yewdell; J R Bennink
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

5.  Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes.

Authors:  R S Midgley; A I Bell; D J McGeoch; A B Rickinson
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

7.  Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

Authors:  R Gavioli; M G Kurilla; P O de Campos-Lima; L E Wallace; R Dolcetti; R J Murray; A B Rickinson; M G Masucci
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

8.  The polymorphism of HLA antigens in the Chinese.

Authors:  T D Lee; T M Zhao; R Mickey; Y P Sun; G Lee; C X Song; D Z Cheng; S Zhou; S Q Ding; D X Cheng
Journal:  Tissue Antigens       Date:  1988-10

9.  Evolution and transmission of stable CTL escape mutations in HIV infection.

Authors:  P J Goulder; C Brander; Y Tang; C Tremblay; R A Colbert; M M Addo; E S Rosenberg; T Nguyen; R Allen; A Trocha; M Altfeld; S He; M Bunce; R Funkhouser; S I Pelton; S K Burchett; K McIntosh; B T Korber; B D Walker
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

10.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

View more
  18 in total

1.  Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes.

Authors:  R S Midgley; A I Bell; D J McGeoch; A B Rickinson
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Specific mutation of a gammaherpesvirus-expressed antigen in response to CD8 T cell selection in vivo.

Authors:  Joy Loh; Daniel L Popkin; Lindsay Droit; Douglas C Braaten; Guoyan Zhao; Xin Zhang; Punit Vachharajani; Nancy Myers; Ted H Hansen; Herbert W Virgin
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

3.  Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples.

Authors:  H Kwok; C W Wu; A L Palser; P Kellam; P C Sham; D L W Kwong; A K S Chiang
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

4.  Human herpesvirus diversity is altered in HLA class I binding peptides.

Authors:  William H Palmer; Marco Telford; Arcadi Navarro; Gabriel Santpere; Paul J Norman
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-29       Impact factor: 12.779

5.  Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.

Authors:  Manuel Albanese; Takanobu Tagawa; Mickaël Bouvet; Liridona Maliqi; Dominik Lutter; Jonathan Hoser; Maximilian Hastreiter; Mitch Hayes; Bill Sugden; Larissa Martin; Andreas Moosmann; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

Review 6.  The human leukocyte antigen class I genes in nasopharyngeal carcinoma risk.

Authors:  Elham Hassen; Ghandri Nahla; Noureddine Bouaouina; Lotfi Chouchane
Journal:  Mol Biol Rep       Date:  2009-05-17       Impact factor: 2.316

7.  Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection.

Authors:  John J Miles; Anna M Bulek; David K Cole; Emma Gostick; Andrea J A Schauenburg; Garry Dolton; Vanessa Venturi; Miles P Davenport; Mai Ping Tan; Scott R Burrows; Linda Wooldridge; David A Price; Pierre J Rizkallah; Andrew K Sewell
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

8.  Genomic sequencing and comparative analysis of Epstein-Barr virus genome isolated from primary nasopharyngeal carcinoma biopsy.

Authors:  Hin Kwok; Amy H Y Tong; Chi Ho Lin; Si Lok; Paul J Farrell; Dora L W Kwong; Alan K S Chiang
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

9.  Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection.

Authors:  Anne L Palser; Nicholas E Grayson; Robert E White; Craig Corton; Samantha Correia; Mohammed M Ba Abdullah; Simon J Watson; Matthew Cotten; John R Arrand; Paul G Murray; Martin J Allday; Alan B Rickinson; Lawrence S Young; Paul J Farrell; Paul Kellam
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

10.  A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.

Authors:  Graham S Taylor; Hui Jia; Kevin Harrington; Lip Wai Lee; James Turner; Kristin Ladell; David A Price; Manjit Tanday; Jen Matthews; Claudia Roberts; Ceri Edwards; Lesley McGuigan; Andrew Hartley; Steve Wilson; Edwin P Hui; Anthony T C Chan; Alan B Rickinson; Neil M Steven
Journal:  Clin Cancer Res       Date:  2014-08-14       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.